In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ProteoTech Inc.

www.proteotech.com

Latest From ProteoTech Inc.

Execs On The Move, February 2015

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (12/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

Building the New Generation of Drugs in Neurodegeneration

Neurodegenerative diseases have emerged as one of the toughest and potentially most attractive frontiers in specialty drug development. Companies interested in the NDD space have the option of pursuing several strategies: disease-modifying therapies, symptom management therapies, or a hybrid approach, in which symptom-modifying drugs provide near-term revenues but also have longer-term potential for disease modification. Given the extraordinary difficulty associated with producing a successful disease-modifying new therapy, drugs aimed at treating symptoms are likely to dominate the NDD space for years. Licensors are rewarding developers with promising symptom modification programs with attractive deals.
BioPharmaceutical

ProteoTech Inc.

While researches continue to debate the molecular causes of Alzheimer's disease, they do agree that pathological deposits of the beta-amyloid protein are responsible for some of the disease's destructive effects. Researchers at the University of Washington believe they have found a novel aproach that interferes with the harmful formation of amyloid deposits, and have founded ProteoTech Inc. to develop proteoglycan technologies.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ProteoTech Inc.
  • Senior Management
  • Roger S Flugel, PhD, CEO
    Dennis L McCurley, COO & CFO
    Alan D Snow, PhD, Pres. & CSO
  • Contact Info
  • ProteoTech Inc.
    Phone: (425) 823-0400
    12040 115th Ave., NE
    Kirkland, WA 98034
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register